Cargando…
Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota
CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of Clostridioides difficile, inhibiting C. difficile toxin production and spore formation. CRS3123 has been evaluated in a multiple-ascending-dose placebo-controlled phase 1 trial. Thirty healthy subjects, ages 18 to...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187627/ https://www.ncbi.nlm.nih.gov/pubmed/31685472 http://dx.doi.org/10.1128/AAC.01395-19 |
_version_ | 1783527203154165760 |
---|---|
author | Lomeli, Barbara K. Galbraith, Hal Schettler, Jared Saviolakis, George A. El-Amin, Wael Osborn, Blaire Ravel, Jacques Hazleton, Keith Lozupone, Catherine A. Evans, Ronald J. Bell, Stacie J. Ochsner, Urs A. Jarvis, Thale C. Baqar, Shahida Janjic, Nebojsa |
author_facet | Lomeli, Barbara K. Galbraith, Hal Schettler, Jared Saviolakis, George A. El-Amin, Wael Osborn, Blaire Ravel, Jacques Hazleton, Keith Lozupone, Catherine A. Evans, Ronald J. Bell, Stacie J. Ochsner, Urs A. Jarvis, Thale C. Baqar, Shahida Janjic, Nebojsa |
author_sort | Lomeli, Barbara K. |
collection | PubMed |
description | CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of Clostridioides difficile, inhibiting C. difficile toxin production and spore formation. CRS3123 has been evaluated in a multiple-ascending-dose placebo-controlled phase 1 trial. Thirty healthy subjects, ages 18 to 45 years, were randomized into three cohorts of 10 subjects each, receiving either 200, 400, or 600 mg of CRS3123 (8 subjects per cohort) or placebo (2 subjects per cohort) by oral administration twice daily for 10 days. CRS3123 was generally safe and well tolerated, with no serious adverse events (SAEs) or severe treatment-emergent adverse events (TEAEs) reported. All subjects completed their assigned treatment and follow-up visits, and there were no trends in systemic, vital sign, or laboratory TEAEs. There were no QTcF interval changes or any clinically significant changes in other electrocardiogram (ECG) intervals or morphology. CRS3123 showed limited but detectable systemic uptake; although absorption increased with increasing dose, the increase was less than dose proportional. Importantly, the bulk of the oral dose was not absorbed, and fecal concentrations were substantially above the MIC(90) value of 1 μg/ml at all dosages tested. Subjects receiving either of the two lower doses of CRS3123 exhibited minimal disruption of normal gut microbiota after 10 days of twice-daily dosing. CRS3123 was inactive against important commensal anaerobes, including Bacteroides, bifidobacteria, and commensal clostridia. Microbiome data showed favorable differentiation compared to other CDI therapeutics. These results support further development of CRS3123 as an oral agent for the treatment of CDI. (This study has been registered at Clinicaltrials.gov under identifier NCT02106338.) |
format | Online Article Text |
id | pubmed-7187627 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-71876272020-04-28 Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota Lomeli, Barbara K. Galbraith, Hal Schettler, Jared Saviolakis, George A. El-Amin, Wael Osborn, Blaire Ravel, Jacques Hazleton, Keith Lozupone, Catherine A. Evans, Ronald J. Bell, Stacie J. Ochsner, Urs A. Jarvis, Thale C. Baqar, Shahida Janjic, Nebojsa Antimicrob Agents Chemother Experimental Therapeutics CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of Clostridioides difficile, inhibiting C. difficile toxin production and spore formation. CRS3123 has been evaluated in a multiple-ascending-dose placebo-controlled phase 1 trial. Thirty healthy subjects, ages 18 to 45 years, were randomized into three cohorts of 10 subjects each, receiving either 200, 400, or 600 mg of CRS3123 (8 subjects per cohort) or placebo (2 subjects per cohort) by oral administration twice daily for 10 days. CRS3123 was generally safe and well tolerated, with no serious adverse events (SAEs) or severe treatment-emergent adverse events (TEAEs) reported. All subjects completed their assigned treatment and follow-up visits, and there were no trends in systemic, vital sign, or laboratory TEAEs. There were no QTcF interval changes or any clinically significant changes in other electrocardiogram (ECG) intervals or morphology. CRS3123 showed limited but detectable systemic uptake; although absorption increased with increasing dose, the increase was less than dose proportional. Importantly, the bulk of the oral dose was not absorbed, and fecal concentrations were substantially above the MIC(90) value of 1 μg/ml at all dosages tested. Subjects receiving either of the two lower doses of CRS3123 exhibited minimal disruption of normal gut microbiota after 10 days of twice-daily dosing. CRS3123 was inactive against important commensal anaerobes, including Bacteroides, bifidobacteria, and commensal clostridia. Microbiome data showed favorable differentiation compared to other CDI therapeutics. These results support further development of CRS3123 as an oral agent for the treatment of CDI. (This study has been registered at Clinicaltrials.gov under identifier NCT02106338.) American Society for Microbiology 2019-12-20 /pmc/articles/PMC7187627/ /pubmed/31685472 http://dx.doi.org/10.1128/AAC.01395-19 Text en Copyright © 2019 Lomeli et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Experimental Therapeutics Lomeli, Barbara K. Galbraith, Hal Schettler, Jared Saviolakis, George A. El-Amin, Wael Osborn, Blaire Ravel, Jacques Hazleton, Keith Lozupone, Catherine A. Evans, Ronald J. Bell, Stacie J. Ochsner, Urs A. Jarvis, Thale C. Baqar, Shahida Janjic, Nebojsa Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota |
title | Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota |
title_full | Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota |
title_fullStr | Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota |
title_full_unstemmed | Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota |
title_short | Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota |
title_sort | multiple-ascending-dose phase 1 clinical study of the safety, tolerability, and pharmacokinetics of crs3123, a narrow-spectrum agent with minimal disruption of normal gut microbiota |
topic | Experimental Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187627/ https://www.ncbi.nlm.nih.gov/pubmed/31685472 http://dx.doi.org/10.1128/AAC.01395-19 |
work_keys_str_mv | AT lomelibarbarak multipleascendingdosephase1clinicalstudyofthesafetytolerabilityandpharmacokineticsofcrs3123anarrowspectrumagentwithminimaldisruptionofnormalgutmicrobiota AT galbraithhal multipleascendingdosephase1clinicalstudyofthesafetytolerabilityandpharmacokineticsofcrs3123anarrowspectrumagentwithminimaldisruptionofnormalgutmicrobiota AT schettlerjared multipleascendingdosephase1clinicalstudyofthesafetytolerabilityandpharmacokineticsofcrs3123anarrowspectrumagentwithminimaldisruptionofnormalgutmicrobiota AT saviolakisgeorgea multipleascendingdosephase1clinicalstudyofthesafetytolerabilityandpharmacokineticsofcrs3123anarrowspectrumagentwithminimaldisruptionofnormalgutmicrobiota AT elaminwael multipleascendingdosephase1clinicalstudyofthesafetytolerabilityandpharmacokineticsofcrs3123anarrowspectrumagentwithminimaldisruptionofnormalgutmicrobiota AT osbornblaire multipleascendingdosephase1clinicalstudyofthesafetytolerabilityandpharmacokineticsofcrs3123anarrowspectrumagentwithminimaldisruptionofnormalgutmicrobiota AT raveljacques multipleascendingdosephase1clinicalstudyofthesafetytolerabilityandpharmacokineticsofcrs3123anarrowspectrumagentwithminimaldisruptionofnormalgutmicrobiota AT hazletonkeith multipleascendingdosephase1clinicalstudyofthesafetytolerabilityandpharmacokineticsofcrs3123anarrowspectrumagentwithminimaldisruptionofnormalgutmicrobiota AT lozuponecatherinea multipleascendingdosephase1clinicalstudyofthesafetytolerabilityandpharmacokineticsofcrs3123anarrowspectrumagentwithminimaldisruptionofnormalgutmicrobiota AT evansronaldj multipleascendingdosephase1clinicalstudyofthesafetytolerabilityandpharmacokineticsofcrs3123anarrowspectrumagentwithminimaldisruptionofnormalgutmicrobiota AT bellstaciej multipleascendingdosephase1clinicalstudyofthesafetytolerabilityandpharmacokineticsofcrs3123anarrowspectrumagentwithminimaldisruptionofnormalgutmicrobiota AT ochsnerursa multipleascendingdosephase1clinicalstudyofthesafetytolerabilityandpharmacokineticsofcrs3123anarrowspectrumagentwithminimaldisruptionofnormalgutmicrobiota AT jarvisthalec multipleascendingdosephase1clinicalstudyofthesafetytolerabilityandpharmacokineticsofcrs3123anarrowspectrumagentwithminimaldisruptionofnormalgutmicrobiota AT baqarshahida multipleascendingdosephase1clinicalstudyofthesafetytolerabilityandpharmacokineticsofcrs3123anarrowspectrumagentwithminimaldisruptionofnormalgutmicrobiota AT janjicnebojsa multipleascendingdosephase1clinicalstudyofthesafetytolerabilityandpharmacokineticsofcrs3123anarrowspectrumagentwithminimaldisruptionofnormalgutmicrobiota |